ILT4

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Retrieved on: 
Monday, April 8, 2024
B cell, Ligand, Patient, CHRS, Tumor microenvironment, LILRB2, Cancer, Macrophage, PD-1, Neonatal Fc receptor, IND, Phenotype, Neoplasm, Poster, ILT4, Vaccine

REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today presented preclinical data for its immuno-oncology pipeline candidate, CHS-1000, a novel ILT4 monoclonal antibody, at the 2024 AACR Annual Meeting being held in San Diego, California. Data presented show CHS-1000 is a potent monoclonal antibody that binds selectively to human ILT4 (also known as LILRB2) with high affinity, efficiently blocking interaction with its ligands and reversing immunosuppressive functions, leading to activation of human dendritic cells and T cells and promoting polarization of macrophages to an inflammatory M1 phenotype.

Key Points: 
  • “Myeloid cell-mediated immunosuppression in the tumor microenvironment is a major contributor to tumor immune invasion and PD-1 resistance.
  • The data presented in this poster demonstrate the potential for CHS-1000 to reverse myeloid suppression and activate an inflammatory immune response.
  • “CHS-1000 is our first internally discovered development candidate, and we are excited to be filing the IND this quarter.
  • ILT4 and CD163, a marker of suppressive (M2) macrophages, are highly expressed in a broad range of solid tumors.

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, February 26, 2024
AAAAI, Injection, KIT, Research, Dermatology, Omalizumab, Eosinophilic esophagitis, B cell, Hypersensitivity, Quality of life, Work, Prurigo nodularis, Loss, DLQI, ILT4, Data, PD-1, Contingency, Inflammation, Cell, Myelocyte, Rockefeller University, Therapy, PN, Allergy, WCI, UAS7, Patient, Dermatology Life Quality Index, CSU, Survival, Congress, Disease, G&A, Itch, SRS, American Academy, Pharmaceutical industry

HAMPTON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Celldex is currently planning two Phase 3 studies of barzolvolimab in CSU, which are expected to initiate this summer.
  • Celldex is currently planning for the initiation of a Phase 2 subcutaneous study in prurigo nodularis (PN) in early 2024.
  • The litigation settlement related loss had a ($0.26) impact on net loss per share for the twelve months ended December 31, 2023.
  • Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2023 are sufficient to meet estimated working capital requirements and fund current planned operations into 2026.

Immune-Onc Therapeutics Announces Clinical Trial Collaboration to Evaluate IO-108 in a Randomized Global Phase 1b/2 Study for First-Line Treatment of Advanced Liver Cancer

Retrieved on: 
Tuesday, February 20, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Bevacizumab, National Comprehensive Cancer Network, Food, Safety, LILRB2, Hepatocellular carcinoma, Therapy, HCC, ILT4, Roche, Patient, Immunotherapy, Cancer, Pharmaceutical industry

Atezolizumab and bevacizumab is the first cancer immunotherapy combination regimen approved by the U.S. Food and Drug Administration for this setting and is the recommended standard of care by the National Comprehensive Cancer Network.

Key Points: 
  • Atezolizumab and bevacizumab is the first cancer immunotherapy combination regimen approved by the U.S. Food and Drug Administration for this setting and is the recommended standard of care by the National Comprehensive Cancer Network.
  • “We are excited to work with Roche to accelerate the development of IO-108,” said Charlene Liao, Ph.D., chief executive officer and board chair of Immune-Onc.
  • “IO-108 has demonstrated clinical activity and an acceptable safety profile across multiple solid tumors as monotherapy and in combination with T cell checkpoint inhibitors.
  • The collaboration marks a significant milestone in establishing IO-108 as the preferred myeloid checkpoint inhibitor for combination with standard of care immunotherapy regimens in solid tumors.”
    Under the collaboration, Roche will sponsor and conduct the global, randomized Phase 1b/2 trial to evaluate the safety, efficacy and pharmacodynamics of IO-108 in combination with atezolizumab and bevacizumab compared to atezolizumab and bevacizumab, the standard of care treatment regimen for advanced liver cancer.

Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 2, 2023
CSU, DLQI, Prurigo, Science, Survival, WCI, KIT, Research, Dermatology Life Quality Index, PN, Contingency, Congress, G&A, Work, B cell, PD-1, Cell, R, Quality of life, European Academy of Management, SD, Prurigo nodularis, Myelocyte, Disease, UCT, Eosinophilic esophagitis, Allergy, Georgia World Congress Center, ILT4, Therapy, Patient, Rockefeller University, SCF, Hypersensitivity, D, Pharmaceutical industry, Vaccine, Rare-earth element, Cryptocurrency, Dermatology

HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • - Phase 2 CSU enrollment complete; topline data by YE 2023 -
    HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
  • In July 2023, Celldex announced that enrollment to the CSU study (n=208) had been completed and that topline data is anticipated by the end of 2023.
  • Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2023 were $235.3 million compared to $252.7 million as of June 30, 2023.

ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002

Retrieved on: 
Tuesday, October 24, 2023
ESMO, Therapy, Infrared spectroscopy correlation table, Trial of the century, KIR3DL1, Pembrolizumab, PD-1, Inflammation, Pharmacokinetics, LILRB1, LILRB2, ILT2, DLT, Safety, Cancer, CMO, ILT4, Patient, Immuno-psychiatry, Pharmaceutical industry, MD

The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.

Key Points: 
  • The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.
  • A second cohort of IOS-1002 in combination with pembrolizumab will be initiated after completion of the fifth dose level.
  • The Phase 1a/b trial is expected to enroll over 120 patients.
  • "We are pleased that the trial is progressing as planned," said Christoph Renner, M.D., CMO and co-founder of ImmunOs Therapeutics.

ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA

Retrieved on: 
Tuesday, October 17, 2023
LILRB1, Merck Sharp & Dohme Federal Credit Union, Immuno-psychiatry, Pembrolizumab, Inflammation, Therapy, Merck & Co., Safety, ILT4, Cancer, LILRB2, Merck, HLA, KIR3DL1, ILT2, Patient, Pharmaceutical industry, MD

IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1.

Key Points: 
  • IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1.
  • ImmunOs is currently enrolling patients in the Phase 1a/b trial, initiated earlier this year, to evaluate the potential of IOS-1002 as a monotherapy and in combination with KEYTRUDA in adult patients with advanced solid tumors.
  • “We are pleased to enter into this agreement for our ongoing Phase 1a/b trial of IOS-1002,” said Christoph Renner, M.D., Chief Medical Officer, and co-founder of ImmunOs.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of Anti-LILRB2 Antibody ES009 in Australia

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Myelocyte, Cancer, Pharmacokinetics, ILT4, Therapy, CSO, Tumor microenvironment, Phenotype, Patient, Biopharmaceutical, LILRB2, Safety, TME, Vaccine

Elpiscience Biopharmaceuticals (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, announced today that the first patient has been dosed in a Phase 1 clinical trial of its anti-LILRB2 monoclonal antibody ES009 in Australia.

Key Points: 
  • Elpiscience Biopharmaceuticals (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, announced today that the first patient has been dosed in a Phase 1 clinical trial of its anti-LILRB2 monoclonal antibody ES009 in Australia.
  • The objective of the trial is to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity.
  • ES009 specifically binds to a unique epitope on human LILRB2 and potently blocks LILRB2 binding to multiple ligands.
  • By blocking LILRB2-mediated inhibitory signaling, ES009 can reprogram myeloid cells from anti-inflammatory phenotype into pro-inflammatory phenotype, and reinvigorate T cell functionalities.

Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 8, 2023
Well, Hypersensitivity, Rockefeller University, Survival, G&A, Omalizumab, Angioedema, KIT, ILT4, Patient, Prurigo nodularis, R, Quality of life, Allergy, Research, European Academy of Allergy and Clinical Immunology, Eosinophil, Prurigo, Neoplasm, PD-1, Kinetics, Skin, Safety, D, Index, Eosinophilic esophagitis, CSU, Contingency, B cell, Cell, Hives, PCE, MTD, Itch, Therapy, Myelocyte, Dysphagia, Clinical trial, Esophagus, EAACI, PN, Physician, UCT, SD, Rare-earth element, Pharmaceutical industry, Vaccine, Beauty salon, Cryptocurrency, Video game, Dermatology

HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • - Phase 2 CSU enrollment completed; topline data by YE 2023 -
    HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
  • In July 2023, Celldex announced that enrollment to the CSU study had been completed.
  • CSU EAACI 2023 Data Summary:
    At EAACI 2023 , data were presented on the complete 24 week experience for all patients.
  • In May 2023, Celldex announced that the first patient had been dosed in the Phase 1 study of CDX-585.

Coherus to Acquire Surface Oncology

Retrieved on: 
Friday, June 16, 2023
Adenocarcinoma, LLP, GSK, Bevacizumab, Non-small-cell lung cancer, FY, SG, Hepatocellular carcinoma, RCC, Survival, Cancer, Arnold, Lung cancer, Head, Latham & Watkins, CCR8, Antibody, Liver cancer, Nasopharyngeal carcinoma, Organization, CHRS, ORR, GSK plc, VEGF, Acquisition, ILT4, MD, Patient, Immunoglobulin G, CVR College of Engineering, Renal cell carcinoma, Growth, Neoplasm, PD-1, IL-27, FDA, Tumor microenvironment, Arnold & Porter, HCC, PD-L1, Novartis, Medical imaging, Vaccine, Pharmaceutical industry, Bank, NSCLC, Surface

– Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing –

Key Points: 
  • – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing –
    – Coherus projects $48 - 53 million of net product revenue in 2Q 2023, and affirms prior FY 2023 revenue and expense guidance –
    REDWOOD CITY, Calif. and CAMBRIDGE, Mass., June 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Surface Oncology, Inc. (Surface, Nasdaq: SURF) today announced that the companies have entered into a definitive merger agreement providing that, at the closing, Coherus will acquire Surface Oncology, a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment.
  • With the agreement to acquire Surface and the expected near-term approval of toripalimab, Coherus is positioned to become one of the very few I-O companies with demonstrated commercial expertise, significant product revenues, and unique, competitively positioned R&D programs addressing critical unmet medical needs,” said Denny Lanfear, Chairman and Chief Executive Officer of Coherus.
  • Novel I-O clinical development will extend Coherus’ reach in oncology and expand physician experience with toripalimab.
  • The press release and live webcast of the conference call can be accessed through a link that is posted on Investors section of the Coherus website: https://investors.coherus.com/ and Investors section of the Surface Oncology website: https://investors.surfaceoncology.com/.

Coherus to Acquire Surface Oncology

Retrieved on: 
Friday, June 16, 2023
Adenocarcinoma, LLP, GSK, Bevacizumab, Non-small-cell lung cancer, FY, SG, Hepatocellular carcinoma, RCC, Survival, Cancer, Arnold, Lung cancer, Head, Latham & Watkins, CCR8, Antibody, Liver cancer, Nasopharyngeal carcinoma, Organization, CHRS, ORR, GSK plc, VEGF, Acquisition, ILT4, MD, Patient, Immunoglobulin G, CVR College of Engineering, Renal cell carcinoma, Growth, Neoplasm, PD-1, IL-27, FDA, Tumor microenvironment, Arnold & Porter, HCC, PD-L1, Novartis, Medical imaging, Vaccine, Pharmaceutical industry, Bank, NSCLC, Surface

– Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing –

Key Points: 
  • – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing –
    – Coherus projects $48 - 53 million of net product revenue in 2Q 2023, and affirms prior FY 2023 revenue and expense guidance –
    REDWOOD CITY, Calif. and CAMBRIDGE, Mass., June 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Surface Oncology, Inc. (Surface, Nasdaq: SURF) today announced that the companies have entered into a definitive merger agreement providing that, at the closing, Coherus will acquire Surface Oncology, a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment.
  • With the agreement to acquire Surface and the expected near-term approval of toripalimab, Coherus is positioned to become one of the very few I-O companies with demonstrated commercial expertise, significant product revenues, and unique, competitively positioned R&D programs addressing critical unmet medical needs,” said Denny Lanfear, Chairman and Chief Executive Officer of Coherus.
  • Novel I-O clinical development will extend Coherus’ reach in oncology and expand physician experience with toripalimab.
  • The press release and live webcast of the conference call can be accessed through a link that is posted on Investors section of the Coherus website: https://investors.coherus.com/ and Investors section of the Surface Oncology website: https://investors.surfaceoncology.com/ .